304 related articles for article (PubMed ID: 28051995)
1. In vitro modelling of familial amyloidotic polyneuropathy allows quantitative detection of transthyretin amyloid fibril-like structures in hepatic derivatives of patient-specific induced pluripotent stem cells.
Hoepfner J; Kleinsorge M; Papp O; Alfken S; Heiringhoff R; Pich A; Sauer V; Zibert A; Göhring G; Schmidt H; Sgodda M; Cantz T
Biol Chem; 2017 Jul; 398(8):939-954. PubMed ID: 28051995
[TBL] [Abstract][Full Text] [Related]
2. Generation of familial amyloidotic polyneuropathy-specific induced pluripotent stem cells.
Isono K; Jono H; Ohya Y; Shiraki N; Yamazoe T; Sugasaki A; Era T; Fusaki N; Tasaki M; Ueda M; Shinriki S; Inomata Y; Kume S; Ando Y
Stem Cell Res; 2014 Mar; 12(2):574-83. PubMed ID: 24531302
[TBL] [Abstract][Full Text] [Related]
3. Involvement of Macrophages in the Pathogenesis of Familial Amyloid Polyneuropathy and Efficacy of Human iPS Cell-Derived Macrophages in Its Treatment.
Suenaga G; Ikeda T; Komohara Y; Takamatsu K; Kakuma T; Tasaki M; Misumi Y; Ueda M; Ito T; Senju S; Ando Y
PLoS One; 2016; 11(10):e0163944. PubMed ID: 27695122
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Therapeutic Oligonucleotides for Familial Amyloid Polyneuropathy in Patient-Derived Hepatocyte-Like Cells.
Niemietz CJ; Sauer V; Stella J; Fleischhauer L; Chandhok G; Guttmann S; Avsar Y; Guo S; Ackermann EJ; Gollob J; Monia BP; Zibert A; Schmidt HH
PLoS One; 2016; 11(9):e0161455. PubMed ID: 27584576
[TBL] [Abstract][Full Text] [Related]
5. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates.
Sousa MM; Cardoso I; Fernandes R; Guimarães A; Saraiva MJ
Am J Pathol; 2001 Dec; 159(6):1993-2000. PubMed ID: 11733349
[TBL] [Abstract][Full Text] [Related]
6. Transthyretin fibrillogenesis entails the assembly of monomers: a molecular model for in vitro assembled transthyretin amyloid-like fibrils.
Cardoso I; Goldsbury CS; Müller SA; Olivieri V; Wirtz S; Damas AM; Aebi U; Saraiva MJ
J Mol Biol; 2002 Apr; 317(5):683-95. PubMed ID: 11955017
[TBL] [Abstract][Full Text] [Related]
7. Wild-type transthyretin significantly contributes to the formation of amyloid fibrils in familial amyloid polyneuropathy patients with amyloidogenic transthyretin Val30Met.
Tsuchiya-Suzuki A; Yazaki M; Kametani F; Sekijima Y; Ikeda S
Hum Pathol; 2011 Feb; 42(2):236-43. PubMed ID: 21056899
[TBL] [Abstract][Full Text] [Related]
8. Relationship between amyloid deposition and intracellular structural changes in familial amyloidotic polyneuropathy.
Misumi Y; Ueda M; Obayashi K; Jono H; Su Y; Yamashita T; Ohshima T; Ando Y; Uchino M
Hum Pathol; 2012 Jan; 43(1):96-104. PubMed ID: 21777941
[TBL] [Abstract][Full Text] [Related]
9. Effect of albumin on transthyretin and amyloidogenic transthyretin Val30Met disposition and tissue deposition in familial amyloidotic polyneuropathy.
Taguchi K; Jono H; Kugimiya-Taguchi T; Nagao S; Su Y; Yamasaki K; Mizuguchi M; Maruyama T; Ando Y; Otagiri M
Life Sci; 2013 Dec; 93(25-26):1017-22. PubMed ID: 24211615
[TBL] [Abstract][Full Text] [Related]
10. Disulfide-bond formation in the transthyretin mutant Y114C prevents amyloid fibril formation in vivo and in vitro.
Eneqvist T; Olofsson A; Ando Y; Miyakawa T; Katsuragi S; Jass J; Lundgren E; Sauer-Eriksson AE
Biochemistry; 2002 Nov; 41(44):13143-51. PubMed ID: 12403615
[TBL] [Abstract][Full Text] [Related]
11. Liver transplantation and new therapeutic approaches for familial amyloidotic polyneuropathy (FAP).
Ando Y
Med Mol Morphol; 2005 Sep; 38(3):142-54. PubMed ID: 16170462
[TBL] [Abstract][Full Text] [Related]
12. Chain reaction of amyloid fibril formation with induction of basement membrane in familial amyloidotic polyneuropathy.
Misumi Y; Ando Y; Ueda M; Obayashi K; Jono H; Su Y; Yamashita T; Uchino M
J Pathol; 2009 Dec; 219(4):481-90. PubMed ID: 19790249
[TBL] [Abstract][Full Text] [Related]
13. A low amyloidogenic E61K transthyretin mutation may cause familial amyloid polyneuropathy.
Murakami T; Yokoyama T; Mizuguchi M; Toné S; Takaku S; Sango K; Nishimura H; Watabe K; Sunada Y
J Neurochem; 2021 Mar; 156(6):957-966. PubMed ID: 32852783
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous nerve biomarkers in transthyretin familial amyloid polyneuropathy.
Ebenezer GJ; Liu Y; Judge DP; Cunningham K; Truelove S; Carter ND; Sebastian B; Byrnes K; Polydefkis M
Ann Neurol; 2017 Jul; 82(1):44-56. PubMed ID: 28598015
[TBL] [Abstract][Full Text] [Related]
15. Familial amyloidotic polyneuropathy and transthyretin.
Nagasaka T
Subcell Biochem; 2012; 65():565-607. PubMed ID: 23225017
[TBL] [Abstract][Full Text] [Related]
16. Steady turnover of amyloid fibril proteins in gastric mucosa after liver transplantation in familial amyloid polyneuropathy.
Tsuchiya-Suzuki A; Yazaki M; Sekijima Y; Kametani F; Ikeda S
Amyloid; 2013 Sep; 20(3):156-63. PubMed ID: 23826783
[TBL] [Abstract][Full Text] [Related]
17. Familial amyloidotic polyneuropathy: protein aggregation in the peripheral nervous system.
João Saraiva M; Mendes Sousa M; Cardoso I; Fernandes R
J Mol Neurosci; 2004; 23(1-2):35-40. PubMed ID: 15126690
[TBL] [Abstract][Full Text] [Related]
18. Clusterin regulates transthyretin amyloidosis.
Lee KW; Lee DH; Son H; Kim YS; Park JY; Roh GS; Kim HJ; Kang SS; Cho GJ; Choi WS
Biochem Biophys Res Commun; 2009 Oct; 388(2):256-60. PubMed ID: 19664600
[TBL] [Abstract][Full Text] [Related]
19. Epigallocatechin-3-gallate as a potential therapeutic drug for TTR-related amyloidosis: "in vivo" evidence from FAP mice models.
Ferreira N; Saraiva MJ; Almeida MR
PLoS One; 2012; 7(1):e29933. PubMed ID: 22253829
[TBL] [Abstract][Full Text] [Related]
20. Evidence of the presence of amyloid substance in the blood of familial amyloidotic polyneuropathy patients with ATTR Val30Met mutation.
Liu J; Lan J; Zhao P; Zheng F; Song J; Zhang P; Sun X
Int J Clin Exp Pathol; 2014; 7(11):7795-800. PubMed ID: 25550818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
